Chester County News and Community Website
RADNOR, PA — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) recently announced plans to file two New Drug Applications (NDAs) in 2024. The filings, supported by advice from regulatory counsel including former …
NRx Pharmaceuticals Plans to File Two New Drug Applications in 2024 Read More RADNOR, PA — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) announced that its management team will participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on June 27, 2024.
NRx Pharmaceuticals to Participate in H.C. Wainwright Neuro Perspectives Conference Read More RADNOR, PA — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) recenlty appointed Dr. Dennis McBride to its Board of Directors. Dr. McBride brings a wealth of experience in neuroscience, medical technology, and …
NRx Pharmaceuticals Welcomes Dr. Dennis McBride to Board Read More RADNOR, PA — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) has posted a new Shareholder Update Letter on its website, inviting interested parties to subscribe to their email alert service for ongoing …
NRx Pharmaceuticals Highlights Ketamine’s Role in Depression Treatment Read More RADNOR, PA — NRx Pharmaceuticals (Nasdaq: NRXP) recently shared its financials and offered updates on its business operations from the first quarter of 2024. On the financial front, the pharmaceutical …
NRx Pharmaceuticals Holds Promise for Investors and Patients Alike Read More RADNOR, PA — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) will attend the EF Hutton Annual Global Conference on May 15, 2024, at The Plaza Hotel, New York City.
NRx Pharmaceuticals to Engage Investors at EF Hutton Annual Global Conference Read More RADNOR, PA — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) will disclose its first quarter 2024 financial achievements and provide a corporate update following the market close on Tuesday, May 14, 2024. …
NRx Pharmaceuticals to Unveil First Quarter Financial Results and Corporate Update Read More RADNOR, PA — NRx Pharmaceuticals (Nasdaq: NRXP) recently highlighted a compelling advantage in safety for its drug NRX-101, in comparison to the standard treatments offered in its latest clinical trial. …
NRx Pharmaceuticals Makes Significant Stride with New Depression Drug, Aims for Accelerated FDA Approval Read More RADNOR, PA — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) disclosed encouraging preliminary outcomes from a study on NRX-101, an investigational drug designated as a breakthrough therapy. The drug demonstrated a promising, …
NRx Pharmaceuticals Breakthrough Drug Shows Potential to Reduce Suicide Risk in Bipolar Depression Patients Read More